<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62395">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02293642</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-268</org_study_id>
    <nct_id>NCT02293642</nct_id>
  </id_info>
  <brief_title>Bone Pain Score Validation Initiative</brief_title>
  <acronym>ARIE</acronym>
  <official_title>Prospective Epidemiology Study to Validate the BOMET-QoL-10 in Patients With Bone Metastasis in Germany</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Translation and validation of the BOMET-QoL-10 questionnaire in Germany and assessment of
      its validity and responsiveness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of this study is to translate the questionnaire and to examine the psychometric
      properties of BOMET-QoL-10 in a German population. Correlations with the EORTC QLQ-C30/BM22
      at the time of enrolment and throughout the study aim to verify that the BOMET-QoL-10 is
      reliable, valid and able to detect stabilization or changes in quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validity and responsiveness of the BOMET-QoL-10 questionnaire in reference to EORTC QLQ-C30/BM-22</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of tumour entity, comorbidity and further parameters on the scores of bone metastasis at baseline</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of BOMET-QoL-10 in patients with / without progression of the disease</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequence effects (i.e. influence on the order questionnaires are filled out)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">370</enrollment>
  <condition>Bone Metastasis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with bone metastases from primary cancers of the breast, kidney, lung
        or prostate
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults patients (â‰¥ 18 years)

          -  Diagnosed cancer of the breast, kidney, lung or prostate

          -  Bone metastases

          -  Estimated life expectancy of at least 6 months

          -  Fluent German speaking, reading and writing

          -  Informed written consent

        Exclusion Criteria:

          -  Patients without bone metastases

          -  Participation in another study involving questionnaires

          -  Patients not able to comply with the assessments specified in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Multiple Sites All Over Germany</name>
      <address>
        <city>Multiple Sites</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 7, 2016</lastchanged_date>
  <firstreceived_date>November 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary cancers of the breast</keyword>
  <keyword>primary cancers of the kidney</keyword>
  <keyword>primary cancers of the lung</keyword>
  <keyword>primary cancers of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
